$ITOS
iTeos Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024124548 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.11M
YoY Change -3.87%
% of Gross Profit
Research & Development $36.69M
YoY Change 19.74%
% of Gross Profit
Depreciation & Amortization $302.0K
YoY Change 0.67%
% of Gross Profit
Operating Expenses $48.80M
YoY Change 12.75%
Operating Profit -$48.80M
YoY Change 12.75%
Interest Expense $8.010M
YoY Change 0.13%
% of Operating Profit
Other Income/Expense, Net -$3.130M
YoY Change -505.97%
Pretax Income -$43.12M
YoY Change 29.0%
Income Tax $2.243M
% Of Pretax Income
Net Earnings -$45.40M
YoY Change 40.99%
Net Earnings / Revenue
Basic Earnings Per Share -$1.05
Diluted Earnings Per Share -$1.05
COMMON SHARES
Basic Shares Outstanding 36.53M 36.52M
Diluted Shares Outstanding 43.14M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $488.7M
YoY Change -18.41%
Cash & Equivalents $123.7M
Short-Term Investments $365.0M
Other Short-Term Assets $13.36M
YoY Change -3.17%
Inventory
Prepaid Expenses
Receivables $35.00M
Other Receivables $7.803M
Total Short-Term Assets $544.9M
YoY Change -11.99%
LONG-TERM ASSETS
Property, Plant & Equipment $5.372M
YoY Change 61.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $160.2M
YoY Change 249.02%
Other Assets $928.0K
YoY Change 5.69%
Total Long-Term Assets $178.2M
YoY Change 204.54%
TOTAL ASSETS
Total Short-Term Assets $544.9M
Total Long-Term Assets $178.2M
Total Assets $723.1M
YoY Change 6.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.154M
YoY Change 109.24%
Accrued Expenses $943.0K
YoY Change -95.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.81M
YoY Change 30.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $54.57M
YoY Change 6.58%
Total Long-Term Liabilities $54.57M
YoY Change 6.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.81M
Total Long-Term Liabilities $54.57M
Total Liabilities $91.39M
YoY Change 15.12%
SHAREHOLDERS EQUITY
Retained Earnings $33.90M
YoY Change -78.16%
Common Stock $37.00K
YoY Change 2.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $631.7M
YoY Change
Total Liabilities & Shareholders Equity $723.1M
YoY Change 6.7%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$45.40M
YoY Change 40.99%
Depreciation, Depletion And Amortization $302.0K
YoY Change 0.67%
Cash From Operating Activities -$37.35M
YoY Change 10.18%
INVESTING ACTIVITIES
Capital Expenditures $94.00K
YoY Change -89.56%
Acquisitions
YoY Change
Other Investing Activities -$91.40M
YoY Change -487.27%
Cash From Investing Activities -$91.49M
YoY Change -503.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -442.0K
YoY Change
NET CHANGE
Cash From Operating Activities -37.35M
Cash From Investing Activities -91.49M
Cash From Financing Activities -442.0K
Net Change In Cash -129.3M
YoY Change 1054.31%
FREE CASH FLOW
Cash From Operating Activities -$37.35M
Capital Expenditures $94.00K
Free Cash Flow -$37.45M
YoY Change 7.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-39401
dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
85523000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12112000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12642000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37272000
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
339
dei Local Phone Number
LocalPhoneNumber
217 0162
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ITOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38027000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36533918
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123744000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
251177000
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
364097000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
48798000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
43280000
us-gaap Operating Expenses
OperatingExpenses
145196000
us-gaap Operating Expenses
OperatingExpenses
123550000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-48798000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-43280000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110196000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110955000
CY2024Q3 itos Grant Income
GrantIncome
631000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
364097000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
364966000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
280739000
CY2024Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
773000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2024Q3 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
759000
CY2023Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
135000
CY2024Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
6271000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
6365000
CY2024Q3 itos Milestone Receivable
MilestoneReceivable
35000000
CY2023Q4 itos Milestone Receivable
MilestoneReceivable
0
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13362000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12236000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
544875000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
550652000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5372000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2024Q3 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
159150000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
159150000
CY2024Q3 us-gaap Long Term Investments
LongTermInvestments
160198000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
100539000
CY2024Q3 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
5880000
CY2023Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
4508000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
274000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5514000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6036000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
928000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
883000
CY2024Q3 us-gaap Assets
Assets
723077000
CY2023Q4 us-gaap Assets
Assets
667588000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7154000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11293000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
943000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
102000
CY2024Q3 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
17608000
CY2023Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
6956000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8306000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8562000
CY2024Q3 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
0
CY2023Q4 us-gaap Payable Investment Purchase
PayableInvestmentPurchase
9787000
CY2024Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
1449000
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
2063000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1354000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1251000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36814000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40014000
CY2024Q3 itos Grants Repayable
GrantsRepayable
6267000
CY2023Q4 itos Grants Repayable
GrantsRepayable
6609000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4174000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4807000
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
44130000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40930000
CY2024Q3 us-gaap Liabilities
Liabilities
91385000
CY2023Q4 us-gaap Liabilities
Liabilities
92360000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36527470
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36527470
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35838080
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35838080
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
37000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
608690000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
463799000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10966000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13240000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
33931000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
124633000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
631692000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001808865
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.035
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
723077000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
667588000
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
35000000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
12595000
CY2024Q3 us-gaap Revenues
Revenues
0
CY2023Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
35000000
us-gaap Revenues
Revenues
12595000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36686000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30638000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107924000
CY2023Q3 itos Grant Income
GrantIncome
631000
itos Grant Income
GrantIncome
2103000
itos Grant Income
GrantIncome
2165000
CY2024Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
172000
CY2023Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
417000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
1867000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
1146000
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
8010000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
8039000
us-gaap Interest Income Other
InterestIncomeOther
23213000
us-gaap Interest Income Other
InterestIncomeOther
23932000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3130000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
771000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-972000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2870000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43115000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33422000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83985000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80842000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2243000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1181000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6717000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1249000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-45358000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32241000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.3
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.3
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43135464
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35783160
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39572673
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35756295
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43135464
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35783160
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39572673
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35756295
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-45358000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32241000
us-gaap Net Income Loss
NetIncomeLoss
-90702000
us-gaap Net Income Loss
NetIncomeLoss
-82091000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2808000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-736000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
392000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2638000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2785000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
646000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1881000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-975000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39765000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32331000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88429000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-85704000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
663332000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5807000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
578000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2006000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
102000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15551000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
652262000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6964000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
218000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
104000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1722000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-34300000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
623526000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7057000
CY2023Q3 itos Stock Issued During Period Value Employee Stock Purchase Plan And Release Of Restricted Stock Units1
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndReleaseOfRestrictedStockUnits1
10000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-736000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
646000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32241000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
598262000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
575228000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7263000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2265000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-832000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-38216000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
541200000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8062000
CY2024Q2 itos Stock Issued During Period Value Employee Stock Purchase Plan And Release Of Restricted Stock Units1
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndReleaseOfRestrictedStockUnits1
2383000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
119574000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-151000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-72000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7128000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
663868000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7543000
CY2024Q3 itos Stock Issued During Period Value Employee Stock Purchase Plan And Release Of Restricted Stock Units1
StockIssuedDuringPeriodValueEmployeeStockPurchasePlanAndReleaseOfRestrictedStockUnits1
46000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2808000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
2785000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-45358000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
631692000
us-gaap Profit Loss
ProfitLoss
-90702000
us-gaap Profit Loss
ProfitLoss
-82091000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
916000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
671000
us-gaap Share Based Compensation
ShareBasedCompensation
22868000
us-gaap Share Based Compensation
ShareBasedCompensation
19828000
itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-8504000
itos Net Accretion Of Available For Sale Debt Securities
NetAccretionOfAvailableForSaleDebtSecurities
-8042000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-9000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-6000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1507000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-751000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
1016000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1881000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1135000
itos Refundable Income Taxes
RefundableIncomeTaxes
96000
itos Refundable Income Taxes
RefundableIncomeTaxes
-4900000
itos Increase Decrease In Milestone Receivable
IncreaseDecreaseInMilestoneReceivable
35000000
itos Increase Decrease In Milestone Receivable
IncreaseDecreaseInMilestoneReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1224000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1653000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4180000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4581000
itos Increase Decrease In Accrued Clinical Trial Costs
IncreaseDecreaseInAccruedClinicalTrialCosts
9870000
itos Increase Decrease In Accrued Clinical Trial Costs
IncreaseDecreaseInAccruedClinicalTrialCosts
638000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-318000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
592000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-621000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
477000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12595000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-3200000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-730000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103678000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89991000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
440596000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
193510000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
297309000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
206265000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1481000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1570000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
83000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144768000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11102000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2450000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
806000
itos Proceeds From Issuance Of Common Stock And Pre Funded Warrants
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrants
119994000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
277000
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
211000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
121956000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
806000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-908000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2554000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-127398000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80637000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251451000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285038000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124053000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
204401000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
2000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
320000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
385000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1782000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
1881000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-975000
itos Offering Costs Previously Included In Prepaid Expenses
OfferingCostsPreviouslyIncludedInPrepaidExpenses
-143000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3576000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5491000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-45400000
us-gaap Net Income Loss
NetIncomeLoss
-90700000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
33900000
CY2024Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
523247000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1978000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
61000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
525164000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
360000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
325000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
364097000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
364966000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
159150000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
160198000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
523247000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
525164000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
281035000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
280739000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
100208000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
100539000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
381243000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
381278000
CY2024Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3000000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8600000
CY2023Q3 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
2700000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8100000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10326000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9078000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4954000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4382000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5372000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4696000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2024Q3 itos Accrued Professional And Other Fees
AccruedProfessionalAndOtherFees
943000
CY2023Q4 itos Accrued Professional And Other Fees
AccruedProfessionalAndOtherFees
102000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
943000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
102000
itos Upfront Payment Received
UpfrontPaymentReceived
625000000
us-gaap Increase Decrease In Commodity Contract Assets And Liabilities
IncreaseDecreaseInCommodityContractAssetsAndLiabilities
0
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
11900000
itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.30
CY2024Q3 itos Repayment Of Grants
RepaymentOfGrants
200000
itos Repayment Of Grants
RepaymentOfGrants
200000
CY2021 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.0012
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
777000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
3542000
itos Grant Income
GrantIncome
2103000
itos Grant Income
GrantIncome
2165000
CY2024Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
773000
CY2023Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
0
CY2024Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6686000
CY2023Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6813000
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2024Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
120000000
CY2024Q2 itos Offering Cost Incurred
OfferingCostIncurred
400000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
20000000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7543000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7057000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22868000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19828000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22900000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19800000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8270220
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.73
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2582470
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
482899
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
29.32
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
412459
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.33
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9957332
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11979000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5645152
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11902000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.26
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.35
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16882000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-20393000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-59690000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-56577000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-26233000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-13029000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-24295000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-24265000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43115000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33422000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83985000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-80842000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2243000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1181000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6717000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1249000
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.052
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.035
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.08
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.015
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.052
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.08
CY2024Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2024Q3 itos Liability For Accrual Of Additional Interest Expense
LiabilityForAccrualOfAdditionalInterestExpense
1100000
itos Liability For Accrual Of Additional Interest Expense
LiabilityForAccrualOfAdditionalInterestExpense
3200000
CY2024Q3 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
7100000
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2024Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2024Q3 itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
400000
itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
1200000
CY2023Q3 itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
300000
itos Operating Leases Rent Expense Net1
OperatingLeasesRentExpenseNet1
900000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0474
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0475
CY2024Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
150000
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
723000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
385000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1782000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
380000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
316000
us-gaap Operating Lease Payments
OperatingLeasePayments
1148000
us-gaap Operating Lease Payments
OperatingLeasePayments
865000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
395000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1581000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1543000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1039000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
852000
CY2024Q3 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
628000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6038000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
510000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5528000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1354000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4174000
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-45358000
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-32241000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-90702000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-82091000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43135464
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35783160
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39572673
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35756295
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43135464
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35783160
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39572673
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35756295
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.3
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.3
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1925499
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1984130
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1661812
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1751070

Files In Submission

Name View Source Status
0000950170-24-124548-index-headers.html Edgar Link pending
0000950170-24-124548-index.html Edgar Link pending
0000950170-24-124548.txt Edgar Link pending
0000950170-24-124548-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
itos-20240930.htm Edgar Link pending
itos-20240930.xsd Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
itos-20240930_htm.xml Edgar Link completed
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable